We’re in Munich 🇩🇪 with a “true” biotech founder, Dominik Schumacher of Tubulis. Not many biotechs in Europe are led by a founder PhD under 40 and have scaled to raising over 100M. I know only two, one is Thomas at Owkin and the other one is Dominik at Tubulis.

We talked about building a champion ADC biotech, the super hot ADC sphere, and the difference between luck and success.

💎 ABOUT THE SPEAKER

Dominik has had an incredible career, which he started from a young age. With the founding of Tubulis, he has won many start-up awards and in 2019 he was awarded MIT’s Innovators Under 35. As a life science investor, he has invested early in many European biotech companies.

🔗 LINKS MENTIONED

- https://curie.bio/ - https://curie.bio
- Tubulis Closes Upsized €128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline - https://tubulis.com/news/tubulis-closes-upsized-e128-million-series-b2-to-accelerate-clinical-development-of-solid-tumor-focused-adc-pipeline/
- BioSpace - Next wave of ADCs - https://www.biospace.com/article/the-next-wave-of-adcs-could-treat-evasive-solid-tumors-/
- BMS axes Eisai ADC pact 3 years after paying $650M for would-be Elahere rival - https://www.fiercebiotech.com/biotech/bms-axes-eisai-adc-pact-3-years-after-paying-650m-would-be-elahere-rival
- Merck’s ADC Pact With Daiichi Hits Regulatory Setback in FDA Rejection - https://www.biospace.com/article/merck-s-adc-pact-with-daiichi-hits-regulatory-setback-with-fda-rejection/
- ADC Space is too crowded? - https://drive.google.com/file/d/1oA23bidvd2G-z2lnAkPLAMZgl1RXLtr9/view?usp=sharing
- Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio ($1.8B cash) - https://ir.genmab.com/news-releases/news-release-details/genmab-broaden-and-strengthen-oncology-portfolio-acquisition
- BIO-Europe Spring 2019: Newcomer Tubulis tackles ADC technology shortcomings - https://www.youtube.com/watch?v=wwr5KMypBHs
- Top 20 Healthcare Specialist Investors - https://drive.google.com/file/d/1r4IwIKvuVUYQaqCZnpm4DtEYyy3LIT7h/view?usp=sharing

📜 TRANSCRIPT
Read the full transcript here: https://flot.bio/episode/dominik-schumacher-tubulis/
💸 DONATE

We welcome donations from individuals and businesses to support our podcast and allow us to create even more content: https://www.paypal.me/PhilipHemme

⭐️ SPONSORSHIP
Ready to amplify your brand to influential leaders in biotech and biopharma? Contact nick@flot.bio and unlock sponsorship opportunities in our podcasts!

🫶 FOLLOW US
- Newsletter: http://eepurl.com/h_fnmH
- LinkedIn: https://www.linkedin.com/company/flot-bio/
- X (Twitter): https://x.com/FlotBio

🙏 LIKE/FOLLOW/REVIEW
Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below.

🎙️ ABOUT FLOT.BIO
Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 15k monthly views. Free.

⏰ TIMESTAMPS

[00:00:00 ] Intro
[00:01:44 ] Entrepreneurial biotech family
[00:08:46 ] Market validation
[00:14:32 ] Why Munich
[00:17:33 ] Founder-led biotechs
[00:25:20 ] Balancing 3 kids
[00:29:31 ] Tubulis & ADCs
[00:38:25 ] ADC space is crowded
[00:46:12 ] Deep Track Capital
[00:48:17 ] Vision for Tubulis
[00:52:59 ] ADC space is hot
[00:58:03 ] Chinese biotech
[01:02:53 ] Luck vs success